PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
Status:
Terminated
Trial end date:
2020-07-11
Target enrollment:
Participant gender:
Summary
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks
can be effective antiviral medication both as a treatment in ambulatory patients and
prophylaxis/treatment in health care workers because it impairs lysosomal function and
reorganizes lipid raft (cholesterol and sphingolipid rich microdomains in the plasma
membrane) content in cells, which are both critical determinants of Emerging Viral Disease
(EVD) infection. This hypothesis is based on a growing literature linking chloroquine to
antiviral activity. It is estimated that enough information exists to launch a clinical trial
of hydroxychloroquine for COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
UnitedHealth Group
Collaborators:
ProHealth Care Associates University of Pennsylvania Perelman School of Medicine